- Brazil's health regulator Anvisa has signed off on the resumption of a clinical trial evaluating Johnson & Johnson's (JNJ +0.2%) COVID-19 vaccine in adult volunteers. The study was paused in October pending the investigation into an unexplained illness of a participant, later deemed unrelated to the vaccine.
- When the trial was halted, only 12 subjects had received either the vaccine or placebo. Up to 7,560 Brazilians could be enrolled.
- J&J's candidate is one of four being testing in Brazil, home of the world's third largest outbreak after the U.S. and and India.
- The U.S. portion of the 60K-subject study has also restarted.
- https://seekingalpha.com/news/3630627-brazil-on-board-resumption-of-j-and-j-covidminus-19-vaccine-study
Tuesday, November 3, 2020
Brazil on board with resumption of J&J COVID-19 vaccine study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.